Tesaro's ovarian cancer drug Zejula added to Cancer Drugs Fund

1st June 2018 Uncategorised 0

Drug is first PARP inhibitor shown to be effective in both patients with and without a BRCA mutation

More: Tesaro's ovarian cancer drug Zejula added to Cancer Drugs Fund
Source: News